Domov › Steatotična bolezen jeter › Maryland
Klinične študije za Steatotična bolezen jeter v Maryland
8 študij za Steatotična bolezen jeter išče udeležence na lokacijah v Maryland.
Mesta v Maryland
Uradno besedilo študije (angleško)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Baltimore
- 89bio Clinical Study Site, Glen Burnie
- 89bio Clinical Study Site, Greenbelt
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Baltimore
- 89bio Clinical Study Site, Glen Burnie
- 89bio Clinical Study Site, Greenbelt
Vključevanje udeležencevFaza 3
Starost 18–80 · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT06318169A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Mercy Medical Center - Baltimore, Baltimore
- Capital Digestive Care - Chevy Chase, Chevy Chase
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Baltimore
- Akero Clinical Study Site, Bethesda
Vključevanje udeležencevFaza 3
Starost 18–80 · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Mid-Atlantic GI Research, Greenbelt
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07288138Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- National Institutes of Health Clinical Center, Bethesda
Vključevanje udeležencevFaza 2Vabljeni zdravi prostovoljci
Starost 18–100 · Vsi spoli · Posodobljeno 10. avg. 2026 · NCT03884075Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
- National Institutes of Health Clinical Center, Bethesda
Vključevanje udeležencevFaza 1Vabljeni zdravi prostovoljci
Starost 21–65 · Vsi spoli · Posodobljeno 20. jul. 2026 · NCT04781322A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Baltimore
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 8. jul. 2026 · NCT06920043Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.